Dr. Annie De Groot, CEO/CSO of EpiVax Inc., will be a keynote speaker at the inaugural Immunogenicity and Immunotoxicity Conference, one of four parallel tracks to the 2nd Novel Immunotherapeutics Summit on January 31 – February 1, 2013 in San Diego, CA. The conference brings together leading experts in industry, academia and the FDA. The conference will cover important progress made in the areas of therapeutic protein immunogenicity and immunotoxicity evaluation, such as: protein aggregation, clinical relevance and assessment of immunogenicity, mitigation of immunogenicity-related risks, biosimilar development, and immunotoxicity evaluation strategies.
For a 30% discount off registration use Dr. De Groot’s special code: ADGEPI35
Dr. De Groot will be presenting a talk titled, “Tregitopes: an Immunomodulation Powerhouse – Regulating Immune Responses to Biologics.” Her talk will identify drivers of immune response to biologics; explore how regulatory T cells can be engaged to suppress immunogenicity and explore why the Tregitope concept represents a paradigm shifting solution for immunogenicity.
CLICK HERE to see our 2012 publications including four papers on Tregitopes.
During January and February, EpiVax will be attending multiple conferences on the West Coast, CONTACT US if you will be in the area and would like to meet!